// App-Quantinova.ai

SAT0193 : A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARS

Researchers

Presenter

  • Y. Tanaka

Principal Investigators

  • S. C. Bae

  • D. Bass

  • M. Chu

  • P. Curtis

  • K. Derose

  • B. Ji

  • R. Kurrasch

  • J. Lowe

  • P. Meizlik

  • D. Roth

Medical Centers

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

  • GlaxoSmithKline plc, Collegeville, United States of America

  • GlaxoSmithKline (at the time of the study), Collegeville, United States of America

  • GlaxoSmithKline, Uxbridge, United Kingdom

Locations

  • Japan

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Somatostatin

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01597622

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved